Studying our galaxy’s ‘water worlds’

Astrophysical observations have shown that Neptune-like water-rich exoplanets are common in our galaxy. These “water worlds” are believed to be covered with a thick layer of water, hundreds to thousands of miles deep, above a rocky mantle.

While water-rich exoplanets are common, their composition is very different from Earth, so there are many unknowns in terms of these planets’ structure, composition and geochemical cycles.

In seeking to learn more about these planets, an international team of researchers, led by Arizona State University, has provided one of the first mineralogy lab studies for water-rich exoplanets. The results of their study have been recently published in the journal Proceedings of the National Academy of Sciences.

“Studying the chemical reactions and processes is an essential step toward developing an understanding of these common planet types,” said co-author Dan Shim, of ASU’s School of Earth and Space Exploration.

The general scientific conjecture is that water and rock form separate layers in the interiors of water worlds. Because water is lighter, underneath the water layer in water-rich planets, there should be a rocky layer. However, the extreme pressure and temperature at the boundary between water and rocky layers could fundamentally change the behaviors of these materials.

To simulate this high pressure and temperature in the lab, lead author and research scientist Carole Nisr conducted experiments at Shim’s Lab for Earth and Planetary Materials at ASU using high pressure diamond-anvil cells.

For their experiment, the team immersed silica in water, compressed the sample between diamonds to a very high pressure, then heated the sample with laser beams to over a few thousand degrees Fahrenheit.

The team also conducted laser heating at the Argonne National Laboratory in Illinois. To monitor the reaction between silica and water, X-ray measurements were taken while the laser heated the sample at high pressures.

What they found was an unexpected new solid phase with silicon, hydrogen and oxygen all together.

“Originally, it was thought that water and rock layers in water-rich planets were well-separated,” Nisr said. “But we discovered through our experiments a previously unknown reaction between water and silica and stability of a solid phase roughly in an intermediate composition. The distinction between water and rock appeared to be surprisingly ‘fuzzy’ at high pressure and high temperature.”

The researchers hope that these findings will advance our knowledge on the structure and composition of water-rich planets and their geochemical cycles.

“Our study has important implications and raises new questions for the chemical composition and structure of the interiors of water-rich exoplanets,” Nisr said. “The geochemical cycle for water-rich planets could be very different from that of the rocky planets, such as Earth.”

Story Source:

Materials provided by Arizona State University. Note: Content may be edited for style and length.

Share Button

Coronavirus: NHS and care staff struggling to access tests

Public Health England plans to offer home testing kits across the UK to improve uptake.

Share Button

Health24.com | WATCH | Coronavirus: What does asymptomatic mean?

The information on Health24 is for educational purposes only, and is not intended as medical advice, diagnosis or treatment. If you are experiencing symptoms or need health advice, please consult a healthcare professional. See additional information.

Share Button

Health24.com | Coronavirus morning update: UIF pays R1.1bn in Covid-19 support, and arrests after masks truck hijacked

WHAT’S HAPPENING IN SA

Cases update: 

The latest number of confirmed cases is 3 300.

According to the latest update, 58 have been recorded in the country.

So far, 121 510 tests have been conducted

READ MORE |All the confirmed cases of coronavirus in SA

Latest news:

More than 1.6 million South African workers are covered by applications already lodged by companies for special coronavirus payouts, the department of labour said on Monday.

According to broad statistics released by the government, 55 268 employers had asked the state to help pay their employees, at an average of a little under 30 employees per company.

As of 16 April the special Temporary Employer/Employee Relief Scheme (TERS) of the Unemployment Insurance Fund (UIF) had paid out a total of R1.1 billion in Covid-19 support, the department said.

That is after processing applications dealing with some 600 000 employees – which means more than 60% of applications, as measured by employees not fully paid by their employers, are yet to be dealt with.

READ MORE | More than 1.6 million South Africans may get Covid-19 payments – with R1.1 billion now paid

The Unemployment Insurance Fund has said nearly half the applications it received for coronavirus-related claims by last week were duplicates, amid concerns from organised labour that the cover was not reaching enough vulnerable workers during the national lockdown. 

Spokesperson for the UIF Lungelo Mkamba said the lockdown was an extraordinary situation, and while the Fund is operating with skeleton staff, it is “doing its best under the circumstances”, through electronic platforms, to process all claims at speed.

But it has received thousands of applications, many of which are duplications of previous applications. 

Others, said Mkamba, do not meet the requirements. Of the applications received so far, just over 40% are being approved. 

“As of Monday 13 April 2020, we have received approximately 39 000 Covid-19 claims, of which 16 000 were duplicates. 23 000 did not the requirements and emails have been sent the applicants. 16 000 claims are currently in various stages of the approval processes,” Mkamba said.

READ MORE | UIF sifts through thousands of duplicate claims as growing unemployment threat looms

Three people have been arrested for allegedly hijacking a truck transporting medical masks in Johannesburg on Saturday.

According to South African Police Services (SAPS) national spokesperson Vish Naidoo, the truck was transporting R500 000 worth of medical masks when it was flagged down by a Hyundai sedan on the Barbara Road off-ramp in Isando.

The truck did not stop, but the sedan cornered the truck and forced it to a halt.

The three hijackers then kicked the driver and passengers out, and fled off in the truck.

READ MORE | 3 arrested for hijacking truck transporting medical masks

There has been a sharp increase in activity on South African roads as the country’s lockdown period wears on.

Vehicle tracking company, Tracker, together with Lightstone, has analysed anonymised and aggregated data from client vehicles that shows a dramatic shift in driver habits during South Africa’s initial and extended lockdown periods.

According to the data, South Africans drastically reduced their driving activity during the initial period of lockdown – the first three days of lockdown saw a 75% decrease in vehicle activity.

But from 15 April, Tracker recorded a substantial increase in trips for commercial vehicles, passenger vehicles, taxis, and busses. 

The most notable increase came in the passenger vehicle category.

READ MORE | Big increase in road traffic over recent days

Gauteng hospitals are gearing up for an increase in Covid-19 patients, and their measures include created extra capacity of more than 550 beds and more than 300 intensive care units at public hospitals, with more bed space on the cards. 

Private hospitals in the province are also expanding their resources, some spending hundreds of millions of rands on essential equipment. 

Public hospitals are screening patients and transferring positive cases to designated hospitals. In Pretoria, this is Steve Biko Academic Hospital, working together with Tshwane District Hospital, and in Johannesburg it is Charlotte Maxeke Hospital and Thembisa Hospital.

The Gauteng Provincial Command Council, a government body set up to respond to the Covid-19 crisis, said “we have cleared some of our existing hospitals and declared them Covid-19 facilities”, creating a capacity of 555 standard beds and 308 intensive care unit (ICU) beds.

READ MORE Covid-19 | Gauteng hospitals ready themselves for increase in patients

WHAT’S HAPPENING IN THE REST OF THE WORLD 

Cases update:

For the latest global data, follow this interactive map from Johns Hopkins University & Medicine.

Late on Monday night, positive cases worldwide were more than 2.46 million, while deaths were close to 170 000.

The United States has the most cases in the world – more than 778 000, as well as the most deaths – more than 41 500.

Spain is now the second country to have more than 200 000 cases.

READ MORE | All the confirmed cases worldwide

Latest news:

Italy on Monday reported its first symbolic drop in the number of people currently suffering from the novel coronavirus since it recorded its first infection in February.

The civil protection service said 108 237 people were either being treated in hospital or were recovering at home after testing positive – down 20 from the total reported on Sunday.

“For the first time, we have seen a new positive development: The number of currently positive has declined,” civil protection service chief Angelo Borrelli told reporters.

The Mediterranean country’s death toll still rose by 454 to 24 114 – second only to the United Sates.

READ MORE | Italy says current virus cases fall for the first time

Chancellor Angela Merkel is “greatly concerned” that virus-fighting discipline among the German public may ebb as the country takes its first steps out of a month-long lockdown, AFP learned from party sources on Monday.

The veteran leader warned against “orgies of discussion about opening up” society, in a telephone conference with leaders of her centre-right CDU party on Monday morning, participants in the call said.

After an apparent race among regional leaders last month to appear the toughest in announcing lockdown measures, some politicians have begun pushing for even faster loosening than the reopening of smaller shops and schools Merkel announced last week.

Business lobbies have been pressuring the government to move faster, but initial steps agreed between Berlin and state capitals are tentative.

READ MORE | Angela Merkel ‘concerned’ as Germany inches to reopen after month-long lockdown

LATEST RESEARCH

New research sheds light on why the experimental drug remdesivir might become the most powerful weapon in the fight against Covid-19: It is highly effective against an enzyme that plays a crucial role in the spread of the new coronavirus.

Remdesivir is one of several drugs being fast-tracked in various coronavirus treatment trials around the world. Just last week, a small, “compassionate use” trial published in the New England Journal of Medicine found the drug improved outcomes for people with Covid-19.

More than two-thirds of 53 severely ill patients showed improvement in oxygen support, the Cedars-Sinai Medical Center researchers said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support machines, the study showed.

The latest research, published in the Journal of Biological Chemistry, explains how remdesivir, developed in 2014 to fight the Ebola epidemic, works against the new coronavirus.

READ MORE | Why remdesivir might be a good bet against Covid-19

Trying to identify animals that are most likely to transmit viruses to humans may not help prevent future pandemics, researchers say.

Instead, the focus should be on specific types of viruses and how they spread, they suggest.

The current coronavirus pandemic is believed to have originated in bats, and most emerging infectious diseases are zoonotic, meaning that they’re spread from animals to humans, according to researchers from the University of Glasgow in Scotland.

This pandemic shows the serious health and economic threat that zoonotic viruses pose, so it’s crucial to learn more about them.

READ MORE | Track viruses, not animal carriers, to prevent future pandemics

HEALTH TIPS (as recommended by the NICD and WHO)

• Maintain physical distancing – stay at least one metre away from somebody who is coughing or sneezing

• Practise frequent hand-washing, especially after direct contact with ill people or their environment

• Avoid touching your eyes, nose and mouth, as your hands touch many surfaces and could potentially transfer the virus

• Practise respiratory hygiene – cover your mouth with your bent elbow or tissue when you cough or sneeze. Remember to dispose the tissue immediately after use.

READ MORE: Coronavirus 101 

Image credit: Getty Images

Share Button

Health24.com | What people with type 1 diabetes need to know about Covid-19

If you or your child has type 1 diabetes, you already have a lot of extra health worries, and now you need to add Covid-19 infections to the list.

You may be wondering if you have a higher risk of catching Covid-19, if you’ll be able to get your diabetes supplies and how you might handle the illness if you do get sick.

Here’s some information to help you get through this trying time:

Is my risk of Covid-19 higher?

Aaron Kowalski, CEO of JDRF (formerly the Juvenile Diabetes Research Foundation), has some good news on this front.

“Healthy type 1 folks aren’t more at risk if they have a reasonable A1C,” he said. An A1C is a blood test that estimates blood sugar control during the past two to three months.

But, for those who are having trouble keeping their A1C down, he added that consistently high blood sugar can make people more susceptible to infection.

Dr Mary Pat Gallagher is director of the paediatric diabetes centre at NYU Langone Health in New York City.

“If you have an A1C that is less than 9.5%, you are not really considered immunocompromised,” she said. “Higher blood sugar levels for more than two weeks can impair immune function.”

But, she cautioned, “None of us has any immunity to this virus. We’re all extremely susceptible, whether or not we have type 1 diabetes.”

What about complications?

While some of the early data from China and Italy seems to suggest that people with diabetes have a higher risk of complications, Gallagher said those findings probably represent older people with type 2 diabetes and additional medical conditions.

“Children appear – regardless of [any other illnesses] – to be doing very well. There are definitely children in the hospital, but their risk of developing serious illness is much lower,” Gallagher noted.

And, no matter your age, if your blood sugar is well-controlled, you probably don’t have a higher risk of Covid-19-specific complications. But getting sick when you have type 1 diabetes is always a challenge.

Having an illness often wreaks havoc on your blood sugar control. Viral illnesses, like the flu, are known to increase your risk of ketones and diabetic ketoacidosis (DKA), so it’s important to be extra vigilant when it comes to your type 1 diabetes management.

Ketones are chemicals that can build up in the body when it breaks down fat for energy. When there are too many ketones, DKA – a potentially life-threatening complication – can occur.

Be aware that medications can raise your blood sugar, and some drugs affect the accuracy of readings on certain continuous glucose monitors.

“Getting sick definitely adds complexity to type 1 diabetes,” Kowalski said. “Having a sick day management plan is important.”

Gallagher recommended getting a 24-hour number for your doctor’s office that you can reach in an emergency. Post it somewhere that’s easy for everyone in the family to see.

Supplies to have on hand

Gallagher advised filling your prescriptions as soon as possible, if you haven’t already. She suggested trying to get a three-month supply. “A lot of insurance companies are lifting prescription time restrictions,” she said.

Supplies you should have on hand typically include:

  • Insulin
  • Back-up long-acting insulin (if you’re currently using a pump)
  • Glucagon
  • Insulin pump supplies (such as reservoirs, infusion sets)
  • Continuous glucose monitor (CGM) sensors
  • Ketone strips
  • Batteries for insulin pumps, CGMs and standard glucose meter
  • Blood sugar test strips (be sure these aren’t expired) and lancets
  • Low blood sugar treatments (such as glucose tabs and juice)
  • Easy-to-digest foods, like crackers, soup or ice pops
  • Fluids with and without sugar (so you have options for both high and low blood sugar situations)

Kowalski said JDRF has been in touch with insulin and device makers, and the supply chain is strong. There are no significant shortage concerns. He said there may be spotty shortages for a few days at a time in some areas because a lot of people have been filling prescriptions all at once, and many have switched from one month at a time to three months.

What to do if you get sick

If you do get sick, call your doctor for more specific instructions on what to do.

Your diabetes sick day management should tell you when to test for ketones. As a general rule, if you’re on an insulin pump and your blood sugar is over 250 milligrams per decilitre (mg/dL), and you haven’t responded to a correction dose of insulin, check your ketones and call your doctor.

If you’re on multiple daily injections and your blood sugar is over 250mg/dL (despite a correction dose of insulin) for more than two or three hours, check for ketones and call your doctor, Gallagher suggested. Someone on your doctor’s team will walk you through what to do next to help bring your blood sugar down.

Gallagher said it’s important to remember that people with type 1 diabetes always need a long-acting insulin (called “basal” insulin in a pump), even when sick. She said you can reduce the basal insulin, but you shouldn’t stop it, especially not for more than several hours without speaking with someone on your diabetes health care team.

If you have abdominal pain, nausea, vomiting, excess fatigue or fruity-smelling breath, call your diabetes doctor right away. These are signs of DKA.

Day by day

Kowalski suggested that everyone follow the guidelines on washing hands, keeping a safe physical distance from others, and getting up and moving. In scary times exercise can be a good way to work off stress, he said.

Gallagher emphasised the need for people with type 1 diabetes and their families to try to get some physical activity every day, while maintaining social distancing rules, of course. An hour is ideal, she said.

And, she said, “There’s a lot of worry about consistent access to food, making it harder to meal plan. It’s also easy to eat poorly when you’re under stress, so try to make good food choices when you can.”

READ | Certain health conditions increase risks for severe coronavirus cases

READ | Why is coronavirus a bigger worry for people with diabetes?

READ | Obesity ups odds for severe Covid-19 in younger patients

Image credit: iStock

Share Button

Health24.com | Can you avoid unwanted weight gain during the Covid-19 pandemic?

Beware of your fridge, pantry and couch during the coronavirus pandemic.

Being cooped up at home with easy access to food can lead to overeating. Couple that with routine housekeeping, working from home, home schooling your kids and tending to loved ones, and it’s a sure-fire recipe for weight gain, experts at the University of Georgia in Athens warn.

“These tasks have been added to our many other responsibilities,” said Emma Laing, director of dietetics in the College of Family and Consumer Sciences. “So, if something has to give as we strive to find our new normal, routines surrounding eating and physical activity might go out the window.”

To stay on track, get up off the couch. Try to set times during the day for physical activity you enjoy, and to eat regular meals and snacks that provide adequate energy and hydration.

Avoid mindless snacking

“In creating this schedule, do so while maintaining flexibility,” Laing said. “It’s important to trust our bodies’ cues for hunger, so listen to those first.”

Try to avoid mindless snacking.

Physical distancing during the coronavirus pandemic doesn’t mean you have to stop exercising. In fact, physical activity is a crucial stress management strategy.

Ali Berg, a Cooperative Extension nutrition and health specialist, pointed out that “physical activity is good for maintaining immunity, in addition to adequate nutrition. Being active is also good for mental health.”

Even though gyms and yoga studios are closed, you can find other ways to be active, said Tracey Brigman, a clinical assistant professor.

“I start each day with a 2-mile walk,” said Brigman. “Anytime I cook, I dance (and embarrass my kids). Music also lifts my spirits, so I don’t stress eat. If I have down time waiting for a timer, I jog around the rooms in my house while I wait.”

Other simple ways to stay active include playing with your pets, finding workouts online or through free apps, playing games with the family – and even cleaning the house.

READ | 5 tips for eating healthier during the coronavirus lockdown

READ | Eat healthy, move your body during coronavirus pandemic

READ | Video doctor visits gain ground during coronavirus pandemic

Image credit: iStock

Share Button

Coronavirus: Masks for public ‘could put NHS supplies at risk’

The hospitals bosses’ warning comes ahead of a review into whether people should be urged to wear them.

Share Button

Infant temperament predicts personality more than 20 years later

Researchers investigating how temperament shapes adult life-course outcomes have found that behavioral inhibition in infancy predicts a reserved, introverted personality at age 26. For those individuals who show sensitivity to making errors in adolescence, the findings indicated a higher risk for internalizing disorders (such as anxiety and depression) in adulthood. The study, funded by the National Institutes of Health and published in Proceedings of the National Academy of Sciences, provides robust evidence of the impact of infant temperament on adult outcomes.

“While many studies link early childhood behavior to risk for psychopathology, the findings in our study are unique,” said Daniel Pine, M.D., a study author and chief of the NIMH Section on Development and Affective Neuroscience. “This is because our study assessed temperament very early in life, linking it with outcomes occurring more than 20 years later through individual differences in neural processes.”

Temperament refers to biologically based individual differences in the way people emotionally and behaviorally respond to the world. During infancy, temperament serves as the foundation of later personality. One specific type of temperament, called behavioral inhibition (BI), is characterized by cautious, fearful, and avoidant behavior toward unfamiliar people, objects, and situations. BI has been found to be relatively stable across toddlerhood and childhood, and children with BI have been found to be at greater risk for developing social withdrawal and anxiety disorders than children without BI.

Although these findings hint at the long-term outcomes of inhibited childhood temperament, only two studies to date have followed inhibited children from early childhood to adulthood. The current study, conducted by researchers at the University of Maryland, College Park, the Catholic University of America, Washington, D.C., and the National Institute of Mental Health, recruited their participant sample at 4 months of age and characterized them for BI at 14 months (almost two years earlier than the previously published longitudinal studies). In addition, unlike the two previously published studies, the researchers included a neurophysiological measure to try to identify individual differences in risk for later psychopathology.

The researchers assessed the infants for BI at 14 months of age. At age 15, these participants returned to the lab to provide neurophysiological data. These neurophysiological measures were used to assess error-related negativity (ERN), which is a negative dip in the electrical signal recorded from the brain that occurs following incorrect responses on computerized tasks. Error-related negativity reflects the degree to which people are sensitive to errors. A larger error-related negativity signal has been associated with internalizing conditions such as anxiety, and a smaller error-related negativity has been associated with externalizing conditions such as impulsivity and substance use. The participants returned at age 26 for assessments of psychopathology, personality, social functioning, and education and employment outcomes.

“It is amazing that we have been able to keep in touch with this group of people over so many years. First their parents, and now they, continue to be interested and involved in the work,” said study author Nathan Fox, Ph.D., of the University of Maryland Department of Human Development and Quantitative Methodology.

The researchers found that BI at 14 months of age predicted, at age 26, a more reserved personality, fewer romantic relationships in the past 10 years, and lower social functioning with friends and family. BI at 14 months also predicted higher levels of internalizing psychopathology in adulthood, but only for those who also displayed larger error-related negativity signals at age 15. BI was not associated with externalizing general psychopathology or with education and employment outcomes.

This study highlights the enduring nature of early temperament on adult outcomes and suggests that neurophysiological markers such as error-related negativity may help identify individuals most at risk for developing internalizing psychopathology in adulthood.

“We have studied the biology of behavioral inhibition over time and it is clear that it has a profound effect influencing developmental outcome,” concluded Dr. Fox.

Although this study replicates and extends past research in this area, future work with larger and more diverse samples are needed to understand the generalizability of these findings.

Share Button

Coronavirus: Dentists facing ‘critical shortage of kit’

Patients with urgent problems are having to “take matters into their own hands”, a dental body says.

Share Button

Researchers repurpose classic chemotherapy drug to overcome cancer therapy resistance

Drug resistance is a major obstacle in cancer treatment — leading to relapse for many patients. In a new study, published online April 20, 2020, in Nature Cell Biology, researchers from the Stowers Institute for Medical Research, Children’s Mercy Kansas City, and The University of Kansas Cancer Center report on a promising new strategy to overcome drug resistance in leukemia, using targeted doses of the widely-used chemotherapy drug doxorubicin.

The study’s researchers found that low doses of the anthracycline antibiotic doxorubicin inhibit the interaction between two molecular pathways that work closely together to promote tumor growth and resistance to therapy. The targeted approach also clears the way for cancer-targeting immune cells to do their work, an unexpected and novel finding, according to the study authors.

“In low doses, doxorubicin actually stimulated the immune system, in contrast with the typical clinical doses, which were immunosuppressive, killing healthy immune cells indiscriminately,” says John M. Perry, PhD, a researcher with the Children’s Mercy Research Institute at Children’s Mercy. He completed his postdoctoral work at Stowers and is first author of the report.

The findings are the result of a decade-spanning collaborative effort among researchers at the Stowers Institute, Children’s Mercy, The University of Kansas Cancer Center and other institutions, evolving from their studies on how normal, healthy stem cells self-renew.

Early in their studies, Stowers Institute Investigator Linheng Li, PhD, and Research Specialist Xi He, MD, showed that the protein kinase Akt could enhance Wnt signaling via phosphorylating beta-catenin, thus promoting tumorigenesis in the gut. Perry further investigated the Wnt/beta-catenin and PI3K/Akt pathways in the hematopoietic (blood-forming) system. Using a mouse model with genetic modifications of the Wnt/beta-catenin and PI3K/Akt pathways, Perry found that the two pathways cooperate to drive stem cell renewal, thus resulting in excessive blood-forming stem cell production. But instead of just expanding the stem cells, the permanent activation of the pathways caused the mice also to develop leukemia. Intrigued, the researchers shifted their focus to inhibiting interaction between those same pathways to target leukemia stem cells.

Many drugs that directly target the Wnt/beta-catenin or PI3K/Akt pathways eventually fail because cancer cells evolve resistance to them, and broadly-acting chemotherapeutic drugs can have harsh side effects and systemic toxicity. The researchers collaborated with Scott Weir, PhD, and Anuradha Roy, PhD, at The University of Kansas (KU) Cancer Center, to search for an alternative among the compounds cataloged in the center’s small molecule library.

“Our idea was to find a drug with the goal of blocking the interaction between Wnt/beta-catenin and PI3K/Akt and reduce the toxicity,” says Li, who serves as liaison between Stowers and the KU Cancer Center and co-leads the center’s cancer biology research program.

The team conducted high-throughput drug screening, which showed that doxorubicin did the best job of inhibiting the interaction between the two pathways. They found that the drug’s inhibitory powers worked at low doses, which offers an advantage over administering it at high doses as a chemotherapeutic drug where it can cause lasting heart damage in some patients.

Samples collected from pediatric leukemia patients at Children’s Mercy were also central to the study. A diagnostic sample was collected from each patient before and after chemotherapy treatment to compare therapy-resistant leukemia stem cells to therapy-sensitive leukemia stem cells. Then the samples were transplanted into mice to test whether they developed leukemia and whether low-dose doxorubicin treatment improved their survival and reduced leukemia development.

“We found that mice receiving patient sample transplants with therapy-resistant leukemia stem cells rapidly developed leukemia, but low-dose doxorubicin treatment improved survival by reducing leukemia stem cells,” Perry says. “However, mice receiving patient sample transplants that did not contain therapy-resistant leukemia stem cells did not respond to low-dose doxorubicin treatment. These results showed that chemoresistant leukemia stem cells from patients could be functionally reduced with low-dose doxorubicin treatment, at least in an in vivo animal model assay.”

After successful testing in mouse models, the researchers worked with Tara Lin, MD, at the KU Cancer Center to conduct a small-scale clinical trial to test low-dose anthracycline treatment on adults with treatment-resistant acute myeloid leukemia (AML). The trial used daunorubicin, a chemotherapy drug in the same class as doxorubicin, which is widely used in treating AML. Bone marrow was collected immediately prior to treatment and again post-treatment. Half of the study participants responded to the treatment and had reduced numbers of leukemia stem cells exhibiting the Akt-activated beta-catenin biomarker.

In addition to these encouraging results, the overarching study also revealed surprising insights into immune escape — a hallmark of cancer development in which cancerous cells evade the immune system and proliferate. Mechanistically, they found that leukemia stem cells express multiple proteins known as immune checkpoints, which turn off immune responses that might otherwise recognize and eliminate leukemia stem cells. Another team member, Fang Tao, PhD, uncovered that beta-catenin binds to multiple immune checkpoint gene loci. Low-dose doxorubicin treatment reduced expression of these immune checkpoints, including PD-L1, TIM3, and CD24, which exposed otherwise resistant leukemia stem cells to immune-mediated cell killing.

Going forward, at Children’s Mercy, Perry is conducting further research to understand ways to screen other drugs that synergize with low-dose doxorubicin to kill resistant cells while reactivating anticancer immunity in pediatric patients. His team has recently launched a clinical trial on low-dose doxorubicin in pediatric patients. At Stowers, the Li Lab is investigating similar strategies for overcoming cancer therapy resistance in solid tumor cancers including breast cancer, glioblastoma, and colon cancer.

“The research holds promise as a more effective strategy to overcome cancer therapy resistance and immune escape that can be used in combination with other cancer therapies including chemotherapy, radiation, and immunotherapy for patients with leukemia and other types of cancer,” Li says.

Low-dose doxorubicin also avoids the harsh side effects of high-dose doxorubicin, potentially offering patients a better quality of life. In high doses, doxorubicin damages the heart muscle. Even when patients survive long-term, highly toxic anticancer treatments often cause long-term health problems and reduced life expectancy.

“Pediatric patients should live another half-century or more, so we need to do a better job of ensuring not only long-term survival, but healthy and productive lives,” Perry says.

Share Button